ACH
TCRR

ArrowMark Colorado Holdings’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-259,672
Closed -$467K – 336
2022
Q3 		$467K Hold
259,672
– – 0.01% 288
2022
Q2 		$753K Hold
259,672
– – 0.01% 275
2022
Q1 		$717K Sell
259,672
-168,416
-39% -$530K 0.01% 299
2021
Q4 		$2M Sell
428,088
-785,410
-65% -$4.91M 0.02% 270
2021
Q3 		$10.3M Buy
1,213,498
+186,370
+18% +$2.63M 0.08% 193
2021
Q2 		$16.9M Buy
1,027,128
+63,522
+7% +$1.28M 0.13% 145
2021
Q1 		$21.3M Sell
963,606
-203,614
-17% -$5.55M 0.16% 125
2020
Q4 		$36.1M Sell
1,167,220
-54,479
-4% -$1.38M 0.28% 91
2020
Q3 		$24.8M Sell
1,221,699
-134,311
-10% -$2.36M 0.24% 96
2020
Q2 		$20.8M Sell
1,356,010
-6,643
-0.5% -$76.6K 0.22% 98
2020
Q1 		$10.5M Buy
1,362,653
+92,887
+7% +$1.14M 0.14% 126
2019
Q4 		$18.1M Buy
1,269,766
+143,459
+13% +$2.22M 0.16% 119
2019
Q3 		$16.9M Buy
1,126,307
+640,975
+132% +$9.98M 0.17% 115
2019
Q2 		$6.95M Buy
485,332
+14,634
+3% +$233K 0.07% 187
2019
Q1 		$8.2M Buy
+470,698
New +$8.35M 0.08% 184

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ArrowMark Colorado Holdings's TCRR Position: Q4 2022 in Review

ArrowMark Colorado Holdings sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 259,672 shares — an estimated $467K sold.

ArrowMark Colorado Holdings first reported a position in TCRR in Q1 2019 and held it in 15 quarters. The position peaked at $36.1M in Q4 2020. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • ArrowMark Colorado Holdings reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 259,672 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $467K.
  • ArrowMark Colorado Holdings first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 15 quarters.
  • ArrowMark Colorado Holdings's TCR2 Therapeutics Inc. Common Stock position peaked at $36.1M in Q4 2020.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.